HR Execs on the Move

Apnimed

www.apnimed.com

 
Apnimed is a clinical-stage company focused on advancing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.apnimed.com
  • 39 John F. Kennedy Street 4th Floor
    Cambridge, MA USA 02138
  • Phone: 617.500.8880

Executives

Name Title Contact Details
Lawrence Miller
Founder, Chief Executive Officer and Board Chair Profile
Ted Harding
Chief Human Resources Officer Profile

Similar Companies

ERT

ERT is a global company specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.

SK Life Sciences

SK Life Sciences is a Fair Lawn, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Blood and Cell Technologies

A global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections. Terumo BCT believes in the potential of blood to do even more for patients than it does today.

Mylan Pharmaceuticals Inc

Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.